PRNewsWire
03 Sept 2026, 00:30 UTC · 4d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Insilico Medicine reported H1 2026 revenue of approximately $106 million, a 287% year-over-year increase, and an adjusted net profit exceeding $51 million. — Achieving the first profitable half-year since listing combined with massive revenue growth represents a significant fundamental shift for a clinical-stage biotech.
+0.80The total contract value of transactions announced by Insilico in 2026 has reached approximately $7.3 billion. — High contract values indicate strong commercial validation of their AI platform by global pharmaceutical partners.
+0.60Insilico Medicine will be included in the HKEX Tech 100 Index effective September 14, 2026. — Index inclusion typically triggers passive inflows from index-tracking funds and increases liquidity and visibility.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
The company's lead drug candidate, Rentosertib, has advanced to Phase III trials for idiopathic pulmonary fibrosis. — Progression to Phase III reduces clinical risk and brings the company closer to potential commercialization of its first AI-discovered drug.
+0.30Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
TechCrunch
1d ago
